Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor

Susannah J Stanway, Atul Purohit, L W Lawrence Woo, Saulat Sufi, David Vigushin, Rebecca Ward, Richard H Wilson, Frank Z Stanczyk, Nicola Dobbs, Elena Kulinskaya, Moira Elliott, Barry V L Potter, Michael J Reed, R Charles Coombes

Research output: Contribution to journalArticle

196 Citations (Scopus)

Abstract

Inhibition of steroid sulfatase (STS), the enzyme responsible for the hydrolysis of steroid sulfates, represents a potential novel treatment for postmenopausal women with hormone-dependent breast cancer. Estrone and DHEA are formed by this sulfatase pathway and can be converted to steroids (estradiol and androstenediol, respectively), which have potent estrogenic properties.
Original languageEnglish
Pages (from-to)1585-92
Number of pages8
JournalClinical Cancer Research
Volume12
Issue number5
DOIs
Publication statusPublished - 2006

Keywords

  • androstenediol
  • breast neoplasms
  • coumarins
  • estradiol
  • estrone
  • neoplasm metastasis
  • neoplasms
  • sulfonamides
  • testosterone

Cite this

Stanway, S. J., Purohit, A., Woo, L. W. L., Sufi, S., Vigushin, D., Ward, R., Wilson, R. H., Stanczyk, F. Z., Dobbs, N., Kulinskaya, E., Elliott, M., Potter, B. V. L., Reed, M. J., & Coombes, R. C. (2006). Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor. Clinical Cancer Research, 12(5), 1585-92. https://doi.org/10.1158/1078-0432.CCR-05-1996